Ad Header



The Pulse of the Pharmaceutical Industry

U.S. FDA to review Teva and Celltrion’s cancer biosimilar drug

Written by: | | Dated: Monday, July 31st, 2017


JERUSALEM (Reuters) – Teva Pharmaceutical Industries and South Korea’s Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.

The companies said the FDA has accepted the filing of CT-P6 with regulatory action expected in the first half of 2018. [nBwc10YFha]

CT-P6, already approved by the Korean Ministry of Food and Drug Safety, is a biosimilar — a copy of a biotech drug — to Roche Holding’s breast cancer and gastric cancer treatment Herceptin. Earlier this month, an advisory panel to the FDA recommended approval of a Herceptin biosimilar from Mylan and Biocon.

Sales of Herceptin were 3.54 billion Swiss francs ($3.65 billion) in the first half of 2017.

Celltrion and Teva last year entered into an exclusive partnership to commercialize CT-P6 as well as CT-P10 — a biosimilar to Roche’s blockbuster biotech cancer drug Rituxan — in the United States and Canada. The FDA is also reviewing a Biologics License Application for CT-P10, with action expected in the first half of 2018.


($1 = 0.9687 Swiss francs)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom